Progress Update: Discovery of direct DUX4 inhibitors using AI-guided covalent chemistry and high-scale proteomics

Posted by Friends of FSH Research on Jun 4, 2026

Report by Dr. Kyle Siebenthall
See also Discovery of direct DUX4 inhibitors using AI-guided covalent chemistry and high-scale proteomics

DUX4 is a protein that drives muscle damage in FSHD, and a drug that blocks its activity would treat the disease at its root cause. However, DUX4 belongs to a class of proteins caled transcription factors that has historica ly resisted drug discovery efforts.

At Talus Bioscience, we have developed a technology caled TF-Scan that measures how drug-like molecules affect transcription factors and thousands of other proteins simultaneously inside living human cels. Combined with an AI system we cal Strategian, which learns from each experiment to predict which molecules are most likely to work, our platform is uniquely suited to finding a DUX4 inhibitor.

With Phase I support from Friends of FSH Research, we built the experimental foundation needed to run AI-guided DUX4 inhibitor screens. We optimized our system to reliably produce and detect DUX4 in human muscle cels, used known biological tool compounds to teach Strategian about DUX4 for the first time, and completed two rounds of AI-predicted compound screening, testing 104 molecules in total. None of these initial candidates inhibited DUX4, but this is expected at an early stage of screening: experience from other difficult protein targets te ls us that multiple screening rounds are typicaly needed before hits (active molecules) emerge, with each round making the AI smarter about what kinds of molecules are most likely to work.

We are now positioned to pursue larger, iterative screens more likely to yield a direct DUX4 inhibitor, and ultimately a potential first-in-class therapy for FSHD.